You are here

Medical Testing

Scientists Are Racing to Find Out if Vaccines will Stop Omicron.

As nations severed air links from southern Africa amid fears of another global surge of the coronavirus, scientists scrambled on Sunday to gather data on the new Omicron variant, its capabilities and — perhaps most important — how effectively the current vaccines will protect against it.

The early findings are a mixed picture. The variant may be more transmissible and better able to evade the body’s immune responses, both to vaccination and to natural infection, than prior versions of the virus, experts said in interviews.

Problem, Solution, SitRep, or ?: 

Omicron symptoms mild so far, says South African doctor who spotted it

South African doctor who first spotted the Covid omicron variant says symptoms seem ‘mild’ so far

Covid symptoms linked to the new omicron variant have been described as “extremely mild” by the South African doctor who first raised the alarm over the new strain.

Dr. Angelique Coetzee, chair of the South African Medical Association, told the BBC on Sunday that she started to see patients around Nov.18 presenting with “unusual symptoms” that differed slightly from those associated with the delta variant, which is the most virulent strain of the virus to date and globally dominant.

“It actually started with a male patient who’s around the age of 33 ... and he said to me that he’s just [been] extremely tired for the past few days and he’s got these body aches and pains with a bit of a headache,” she told the BBC.

Problem, Solution, SitRep, or ?: 

WHO statement on clasification Classification of Omicron : SARS-CoV-2 as Variant of Concern

WHO statement:

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

The Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is an independent group of experts that periodically monitors and evaluates the evolution of SARS-CoV-2 and assesses if specific mutations and combinations of mutations alter the behaviour of the virus. The TAG-VE was convened on 26 November 2021 to assess the SARS-CoV-2 variant: B.1.1.529.

The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. The epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant. In recent weeks, infections have increased steeply, coinciding with the detection of B.1.1.529 variant. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021.

Problem, Solution, SitRep, or ?: 

SARS-CoV-2 antibody levels predict COVID vaccine efficacy, study finds

 

SARS-CoV-2 antibody concentrations predict COVID-19 vaccine effectiveness, with higher levels correlating with greater protection, according to an ongoing US phase 3 clinical trial yesterday in Science.

A team led by researchers from Fred Hutchinson Cancer Research Center in Seattle evaluated 30,420 adult recipients of the Moderna mRNA COVID-19 vaccine at 99 centers for neutralizing and binding antibodies as correlates of risk for, and protection against, infection.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Medical Testing
howdy folks
Page loaded in 0.660 seconds.